NLY01

DRUG4 trials

Sponsors

Neuraly, Inc., Johns Hopkins University

Conditions

Diabetes Mellitus, Type 2Multiple SclerosisParkinson DiseaseSafety and Tolerability in Healthy VolunteersType2 Diabetes

Phase 1

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

CompletedNCT03672604

Neuraly, Inc.Safety and Tolerability in Healthy Volunteers

Start: 2018-09-19End: 2019-07-30Updated: 2019-09-30

Phase 2

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

CompletedNCT04154072

Neuraly, Inc.Parkinson Disease

Start: 2020-02-27End: 2023-02-14Updated: 2024-09-19

A Study With NLY01 in Subjects With Type 2 Diabetes

CompletedNCT04159766

Neuraly, Inc.Diabetes Mellitus, Type 2, Type2 Diabetes

Start: 2019-10-16End: 2020-12-04Updated: 2021-03-02

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

RecruitingNCT07497399

Johns Hopkins UniversityMultiple Sclerosis

Start: 2026-04-28End: 2030-01-01Target: 120Updated: 2026-07-17

Related Papers

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

2024-01-0188 citations